Filing Flows › Comparisons › DNA vs RXRX
Ginkgo Bioworks Holdings vs Recursion Pharmaceuticals: DNA and RXRX compared
Ginkgo Bioworks Holdings is the larger company: $20.2M of revenue in its latest quarter (Q2 2026) against $18.6M for Recursion Pharmaceuticals (Q3 2026). Recursion Pharmaceuticals is growing faster (+258% against -48% a year earlier). Ginkgo Bioworks Holdings is more profitable, with an operating margin of -290.5% against -663.9%.
Where the money goes: DNA and RXRX
Ginkgo Bioworks Holdings (DNA) · Q2 2026
Ginkgo Bioworks Holdings, Q2 2026: revenue $20.2M (-48% year over year), operating margin -290.5%, net loss $46.7M, operating cash flow −$44.3M. The chart follows the revenue to costs, profit and cash.
Recursion Pharmaceuticals (RXRX) · Q3 2026
Recursion Pharmaceuticals, Q3 2026: revenue $18.6M (+258% year over year), operating margin -663.9%, net loss $119M, operating cash flow −$77.4M. The chart follows the revenue to costs, profit and cash.
| Ginkgo Bioworks Holdings (DNA) | Recursion Pharmaceuticals (RXRX) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $20.2M | $18.6M |
| Revenue growth, Y/Y | -48% | +258% |
| Operating margin | -290.5% | -663.9% |
| Net earnings | −$46.7M | −$119M |
| Net margin | -231.7% | -641.6% |
| Operating cash flow | −$44.3M | −$77.4M |
Where the revenue comes from
Recursion Pharmaceuticals
- Operating revenue: $18.1M (97%)
- Grant revenue: $497K (3%)
Questions
Which is bigger, Ginkgo Bioworks Holdings or Recursion Pharmaceuticals?
Ginkgo Bioworks Holdings is the larger company: $20.2M of revenue in its latest quarter (Q2 2026) against $18.6M for Recursion Pharmaceuticals (Q3 2026).
Is Ginkgo Bioworks Holdings or Recursion Pharmaceuticals growing faster?
Recursion Pharmaceuticals is growing faster (+258% against -48% a year earlier).
Which is more profitable, Ginkgo Bioworks Holdings or Recursion Pharmaceuticals?
Ginkgo Bioworks Holdings is more profitable, with an operating margin of -290.5% against -663.9%.
More: Ginkgo Bioworks Holdings earnings · how Ginkgo Bioworks Holdings makes money · Recursion Pharmaceuticals earnings · how Recursion Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 6, 2026; 10-Q filed Nov 2, 2026). Fiscal quarters can end on different dates. Not investment advice.